Shares in psychedelic drug developer Compass Pathways are sliding today after it announced that it will slash its headcount by 30% and focus all its efforts on its treatment-resistant depression (TRD) ...

Compass Coffee, the beleaguered D.C.-based chain, has a new owner. Elizabeth L. Gunn, a U.S. bankruptcy judge for the District of Columbia, approved the sale Thursday to London-based giant Caffè Nero, ...

Compass Pathways has announced that its investigational psilocybin treatment has successfully met its primary endpoint in a second Phase 3 clinical trial moving it one step closer to FDA submission.

The American Depositary Shares ("ADS") of the United Kingdom-based biotech Compass Pathways plc (CMPS) are soaring today, after management announced its psychedelic drug candidate COMP006 had met the ...

Lawmakers urge DOJ to detail its review of the $1.6B Compass-Anywhere merger, citing risks to competition and housing costs. The lawmakers say the letter comes after reports that former assistant ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min It beat out five others after ...

COMPASS Pathways plc operates as a biotechnology company that focuses on mental health in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy, which is in Phase III ...

Compass, Inc. engages in the provision of an online real estate platform. Its platform provides an integrated suite of software for customer relationship management, marketing, client service, ...

Compass Pathways Plc is a biotechnology company, which provides mental health care services. It focuses on improving the lives of those who are suffering with mental health challenges and who are not ...

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.